Candel Therapeutics, Inc. (CADL) AI Stock Analysis

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer patients. Its lead candidate, CAN-2409, is undergoing clinical evaluation across multiple indications: Phase II trials for pancreatic cancer and lung cancer, Phase III trials for prostate cancer, and a completed Phase Ib/II trial for high-grade glioma. A second asset, CAN-3110, is in Phase I clinical trials for recurrent glioblastoma. The company also operates the enLIGHTEN Discovery Platform, an HSV-based platform using human biology and advanced analytics to create viral immunotherapies for solid tumors. Formerly known as Advantagene, Inc., the Needham, Massachusetts-based company rebranded in November 2020.

Candel has minimal commercial revenue, generating $125,000 annually from FY2019 through FY2022 before revenue fell 75.2% to $31,000 in FY2023. Over that four-year span, revenue posted a CAGR of -29.4%. Net losses deepened over time, rising from -$8.2M in FY2019 to -$37.9M in FY2023, accompanied by negative net margins of -122383.9% in FY2023. Research and development expenses increased from $6.6M in FY2019 to $24.5M in FY2023. Operating cash outflow expanded from -$5.2M in FY2019 to -$34.2M in FY2023, while free cash flow reached -$34.7M. Over the trailing twelve months through June 30, 2026, revenue stood at $31,000 with diluted EPS of -$1.46.

As of June 30, 2026, Candel held $201.6M in cash and short-term investments, resulting in net cash of $152.0M after subtracting $49.5M in total debt. Shareholders' equity was $126.1M against total assets of $208.1M. The company maintains strong liquidity with a current ratio of 16.09 and a debt-to-equity ratio of 0.39. In FY2025, capital expenditures totaled $587,000. Over a 5-year period, the company's share count increased by 114.0%.

At a share price of $8.19 as of October 16, 2026, Candel trades at a market capitalization of $626.7M and an enterprise value of $711.8M. The stock trades at a forward P/E of 43.5x, compared to 17.3x for the median of its US-listed Healthcare peers. Its price-to-sales multiple is 436.4x, well above the peer median of 4.1x, and its EV-to-revenue ratio is 822.0x. Over the past year, CADL gained 51.1%, outperforming the S&P 500's return of 16.8%. However, its 5-year return of -16.7% lags the S&P 500's 83.0% gain.

Wall Street coverage includes 9 Strong Buy ratings, with zero Buy, Hold, Sell, or Strong Sell recommendations. The mean price target is $21.75, representing an upside of 165.6% from the closing price of $8.19 on October 16, 2026. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$1.08 on $0 in revenue. For the following fiscal year, analysts forecast an EPS of -$0.62 and revenue of $44.3M. The company beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 12, 2026.

This page is an AI-written research summary of Candel Therapeutics, Inc. (CADL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CADL income statement, CADL balance sheet, CADL key metrics, CADL analyst forecast, CADL chart. See the CADL stock overview for the latest quote and news.